Systemic adjuvant therapy for high-risk cutaneous melanoma

Area of Science:

• Oncology
• Dermatology
• Clinical Trials

Background:

• Cutaneous melanoma incidence is rising, posing a significant mortality risk.
• Early-stage melanoma is curable by surgery, but advanced stages (IIB-IV) require systemic adjuvant therapy.
• High-dose interferon-α, previously used, is no longer standard due to toxicity and limited efficacy compared to newer agents.

Purpose of the Study:

• To review completed and ongoing phase III adjuvant therapy trials for resected melanoma.
• To discuss neoadjuvant therapy for locoregionally advanced melanoma.
• To explore predictive and prognostic melanoma biomarkers in the adjuvant setting.

Main Methods:

• Review of completed and ongoing phase III clinical trials in adjuvant melanoma therapy.
• Discussion of neoadjuvant therapy strategies.
• Exploration of recent biomarker studies relevant to melanoma prognosis and treatment response.

Main Results:

• Adjuvant ipilimumab (10 mg/kg) improved relapse-free survival (RFS) and overall survival (OS) but with high toxicity; 3 mg/kg was equally effective and less toxic.
• Nivolumab, pembrolizumab, and dabrafenib plus trametinib show improved RFS compared to ipilimumab (10 mg/kg) or placebo for stages III-IV melanoma.
• Pembrolizumab has gained approval for resected stages IIB-IIC melanoma based on significant RFS benefits.

Conclusions:

• Current adjuvant therapy for resected melanoma has shifted towards immune checkpoint inhibitors (nivolumab, pembrolizumab) and targeted BRAF-MEK inhibitors.
• These newer agents offer improved RFS and OS with varying toxicity profiles and are increasingly replacing older treatments.
• Future research focuses on optimizing adjuvant and neoadjuvant strategies and identifying biomarkers to personalize melanoma treatment.